Focused On-demand Library for Ammonium transporter Rh type A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q02094

UPID:

RHAG_HUMAN

Alternative names:

Erythrocyte membrane glycoprotein Rh50; Erythrocyte plasma membrane 50 kDa glycoprotein; Rhesus blood group family type A glycoprotein; Rhesus blood group-associated ammonia channel; Rhesus blood group-associated glycoprotein

Alternative UPACC:

Q02094; B2R8T8; O43514; O43515; Q7L8L3; Q9H454

Background:

The Ammonium transporter Rh type A, also known as Erythrocyte membrane glycoprotein Rh50, plays a pivotal role in the stability and shape of the erythrocyte membrane. This protein is a component of the ankyrin-1 complex and is involved in the transport of ammonium and CO2 across the erythrocyte membrane. Its ability to leak monovalent cations and regulate RHD membrane expression underscores its significance in erythrocyte physiology and the rhesus blood group antigen expression.

Therapeutic significance:

Given its crucial role in erythrocyte membrane stability and ion transport, the Ammonium transporter Rh type A is linked to diseases such as Regulator type Rh-null hemolytic anemia and Overhydrated hereditary stomatocytosis. Understanding the role of this protein could open doors to potential therapeutic strategies for these red blood cell disorders.